RECRUITING

Safety and Efficacy of Measles, Mumps, Rubella Vaccination in Pediatric Heart Transplantation Patients

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The study is an interventional, non-randomized assessment of safety and efficacy of live Measles, Mumps and Rubella (MMR) vaccine in subjects aged 12-months to 17 years who have undergone heart transplantation. Subjects who provide permission/assent will receive the commercial MMR vaccine according to product indication and labeling.

Official Title

Safety and Efficacy of Measles, Mumps, Rubella Vaccination in Pediatric Heart Transplantation Patients

Quick Facts

Study Start:2025-09-11
Study Completion:2027-09-11
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT07195032

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:1 Year to 17 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:CHILD
Inclusion CriteriaExclusion Criteria
  1. * Received a heart transplant
  2. * At least 1 year after transplant
  3. * At least 1 year after antibody-mediated rejection treatment (intravenous immune globulin, rituximab, bortezomib, plasmapheresis, carfilzomib, eculizumab, daratumumab)
  4. * At least 1 year from anti-thymocyte globulin
  5. * At least 6 months after pulse dose steroid treatment or basiliximab treatment
  6. * No history of MMR vaccination OR History of MMR vaccination but seronegativity for measles at time of inclusion
  7. * Clinically well
  1. * History of repeated infections necessitating adjustment in immunosuppression to non-standard regimen, including single agent immunosuppression and modified trough levels.
  2. * History of anaphylactic reaction to MMR vaccination

Contacts and Locations

Principal Investigator

Victoria Blazek, PharmD, BCPPS
PRINCIPAL_INVESTIGATOR
Children's Mercy Hospital Kansas City

Study Locations (Sites)

Children's Mercy Hospital
Kansas City, Missouri, 64108
United States

Collaborators and Investigators

Sponsor: Children's Mercy Hospital Kansas City

  • Victoria Blazek, PharmD, BCPPS, PRINCIPAL_INVESTIGATOR, Children's Mercy Hospital Kansas City

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-09-11
Study Completion Date2027-09-11

Study Record Updates

Study Start Date2025-09-11
Study Completion Date2027-09-11

Terms related to this study

Keywords Provided by Researchers

  • Measles
  • Mumps
  • Rubella
  • Live vaccine
  • Heart transplant

Additional Relevant MeSH Terms

  • Heart Transplant Infection Prevention